Skip to end of metadata
Go to start of metadata



Dial-in Number

  • One tap mobile
    +13126266799,,3231998494# US (Chicago)
    +13462487799,,3231998494# US (Houston)
  • Dial by your location
    +1 312 626 6799 US (Chicago)
    +1 346 248 7799 US (Houston)
    +1 669 900 6833 US (San Jose)
    +1 929 436 2866 US (New York)
    +1 253 215 8782 US
    +1 301 715 8592 US
    Meeting ID: 323 199 8494
    Find your local number:

Web session

HL7 Antitrust Policy

Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).


Please include your organization in your Zoom name.

  • Click on your picture/name in Zoom
  • Click on rename
  • enter <name> - <organization>
Danielle BancroftBest Practice Software
Melva Peters (Chair)Jenaker Consultingx
Jean Duteau Duteau Designx
John HatemIndependent Consultantx
Scott Robertson Kaiser Permanentex
Christof GessnerHL7 Germany
Corey SpearsMITREx
Dave HillMITRE
Frank McKinneyPOCPx
Isaac VetterEpic
Joe QuinnSmile CDR
Lawrence LoColumbia University HIT Student
Margaret WeikerNCPDP
Matt SzczepankiewiczEpicx
Peter SergentHL7 New Zealandx
Reed D. GelzerTrustworthy EHR
Shelly SpiroPharmacy HIT Collaborativex
Stephen ChuADHAx
Tim McNeilSurescriptsx
Kim RobertsPharmacy HIT Collaborativex
Kent BulzaWell Healthx
Phung Matthews3Mx
Jack BrashierEpic
Emmanuel Obasuyi

Joel MontavonPQA
Robb YoungPharmID
Christopher Isong

Gary SchoettmerNetRx
Courtney BlandCVS / Aetnax
Mark NeumuthAetnax
Ed MillikanFDAx
Sanket RavalCVS / Aetnax

Agenda Items and Notes

Outstanding Action Item List

Meeting Notes from previous meeting

2022-05-23 Agenda/Meeting Notes -  accepted by acclimation general consent

Project Review

Project Proposals

Project Scope Statements

External Meeting Review

Catalog Updates (John Hatem)

  • - Catalog group has been updating the example for one of the medication use cases in the IG.  Use case #6: all meds licensed for use within a jurisdiction. 
  • - no meeting last week; next meeting is this Friday, June 10

Workflow Update (John Hatem) 

  • - Discuss contract issues.  No Pharmacy specific issues discussed. 
  • - No meeting this week.

Healthcare Product Update (John Hatem)

  • -  Discussed SupplyDelivery resource requirements.  No Pharmacy specific issues discussed. 
  • - discussed trackers for various resources, BDP, Device.  No pharmacy specific issues discussed this week. 

EHR conformant reconciled medication list (cRML)

  • - no update

NCPDP Updates (NCPDP Members)

WG18 Patient Consent TG:

    • Addition of Consent to HL7 Specialty Rx FHIR IG  will be balloted as a new version of the Specialty Medication Enrollment Guide in September
    • Connectathon
      • New application was created that illustrates the content of the implementation guide and it demonstrates how the application will use the standard that is defined to request the consent and provide the appropriate consent form to the clinic.
      • The clinic can see the request and work it in to the workflow process, update the request, complete the request, and view it.
      • Focus is on the exchange process while the patient is at the clinic
      • In this process there is still exchange of PDFs
    • Link for Consent Simulator - Patient Requester View
      • From this page it is possible to view the form, submit request and view the status of consent
    • There will be a discussion with the HL7 Community Based Care and Privacy WG in the next couple of weeks to review the plan and what was learned at the Connectathon
      • They will be co-sponsoring the effort to add consent to the guide and take this to ballot
    • NCPDP Meetings are scheduled for June 9, June 23, July 7, and July 21st at 11:00 am US Central Time

MC Consumer and Provider RTPB Standards Monitoring Sub-Task Group

    • HL7® FHIR® Jira tickets status for RTPB Standard vs Consumer RTPB Check Imp Guide gaps have been submitted. Waiting on CARIN Alliance. The sub-TG continues to monitor state legislation and regulations.
    • NCPDP Meetings are scheduled for June 13, June 27, July 11 and July 25 at 12:00 pm US Central Time

WG14 Consultant Pharmacist TG

    • NCPDP TG decided to continue with the HL7/NCPDP guidance document and possibly tackle an IG at a later date.
    • NCPDP meetings are scheduled for June 16, June 30, and July 14 at 10:00 am US Central Time

WG18 Specialty Requirements for ePrescribing Task Group

    • This is rolled into the Patient Consent Task Group at this point in time.

All NCPDP Meeting information can be obtained at


Pharmacy Templates

  • - no update

PDex Formulary (Corey)

  • - Discuss Formulary Block vote 4
    • watch for block vote on Pharmacy list
    • one or two other issues.  once resolved and after block vote, next will be a request for publication
    • Group had a long discussion about issues related to how some drugs are difficult to find with current implementation due to the way that RxNorm represents those drugs.  There may be a resolution but this requires further discussion and trackers will be created to represent these specific examples.  One flavor of this issue is seen when two NDC codes map to one RxCui (note that this is not a rare occurrence) 
    • Block Vote for all items except Jira 34758:  Motion:  Scott Robertson / Corey Spears ; Vote:  14-0-1
    • Jira 34758 - note this item has an updated value set described by Corey on the call.  Motion: Scott Robertson / Corey Spears;  Vote: 14-0-1
    • Corey will update the specific jiras with the ballot resolutions. 

Pharmacist Consult Note (Scott)

    • WG 14 Consulting Pharmacist Interoperability Task group call on reviewed the question of FHIR IG vs Guidance Document.  
      • FHIR IG may be "more visible" to FHIR-focused developers/vendors and may provide development advantages (e.g., constructs in the IG to use in development".  However, there is no current support for ongoing maintenance of a FHIR IG.
      • The Guidance Document is near completion, currently working on verifying mapping and adding use cases.  Ongoing maintenance is not an issue for a Guidance Document.
      • After considerable discussion, the TG voted to go to ballot with the current Guidance Document (current PSS).  May bring forward the FHIR IG when resources for ongoing support are found.

FHIR (Group)

Trackers - link to pharmacy unresolved Jira trackers (see trackers for details / resolutions)

Any Other Business

Next meeting: